Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. 
The ARCUS technology platform allows for delivery of medication through inhalation. It has been used in clinical trials across a broad spectrum of applications: local and systemic disease targets, large and small molecules, and a wide range of doses. The Company has two clinical-stage programs that use the ARCUS technology: CVT-301 (symptoms of OFF periods in Parkinson’s disease) and CVT-427 (acute treatment of migraine).

Type
Public
HQ
Ardsley, US
Founded
1995
Size (employees)
597 (est)
Website
acorda.com
Acorda Therapeutics was founded in 1995 and is headquartered in Ardsley, US
Report incorrect company information

Acorda Therapeutics Office Locations

Acorda Therapeutics has offices in Waltham, South San Francisco, Ardsley and Chelsea
Ardsley, US (HQ)
420 Saw Mill River Rd
Chelsea, US
190 Everett Ave
South San Francisco, US
701 Gateway Blvd
Waltham, US
283 Bear Hill Rd
Show all (4)
Report incorrect company information

Acorda Therapeutics Financials and Metrics

Acorda Therapeutics Financials

Acorda Therapeutics's revenue was reported to be $588.29 m in FY, 2017
USD

Revenue (FY, 2017)

588.3 m

Gross profit (FY, 2017)

453.2 m

Gross profit margin (FY, 2017), %

77%

Net income (FY, 2017)

(223.4 m)

EBIT (FY, 2017)

(232.8 m)

Market capitalization (20-Apr-2018)

1.1 b

Cash (31-Dec-2017)

307.1 m

EV

793.3 m
Acorda Therapeutics's current market capitalization is $1.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

336.4 m401.5 m492.7 m519.6 m588.3 m

Revenue growth, %

19%23%5%

Cost of goods sold

66 m80 m92.3 m107.5 m135.1 m

Gross profit

270.4 m321.5 m400.4 m412.1 m453.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

84.9 m80.5 m97.1 m106 m99.9 m113.7 m148.2 m115.9 m127.5 m135.6 m119.4 m139.4 m

Cost of goods sold

17.2 m15.5 m18.9 m20.6 m18.4 m22.7 m24.7 m23.2 m26.4 m27.6 m25.2 m29.7 m

Gross profit

67.7 m65 m78.2 m85.4 m81.4 m91 m123.5 m92.7 m101 m108 m94.2 m109.8 m

Gross profit Margin, %

80%81%81%81%82%80%83%80%79%80%79%79%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

48 m182.2 m153.2 m158.5 m307.1 m

Accounts Receivable

1 m71.3 m

Inventories

43.1 m37.5 m

Current Assets

367.3 m409.1 m451.3 m272.7 m441.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

46.3 m44.4 m274.6 m53.3 m61.5 m76.2 m89.8 m431.4 m137.4 m127.9 m133.6 m141.1 m

Inventories

25.6 m30.5 m30.8 m26.6 m45.3 m48.6 m46.8 m

Current Assets

387.8 m363.4 m693.1 m843.9 m423.8 m427.6 m429.6 m544.3 m263.2 m238 m248.2 m255.6 m

PP&E

17.8 m16.4 m15.8 m17.1 m45.9 m44.5 m42.4 m38 m36.8 m35.8 m37.1 m37.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

16.4 m17.7 m11.1 m(35.6 m)(223.4 m)

Depreciation and Amortization

7 m8.5 m15 m21.6 m23.2 m

Inventories

(10.2 m)(6.7 m)5.5 m

Accounts Payable

59.9 k59.9 k37.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

10.3 m703 k5.4 m17.3 m(3.1 m)(2.1 m)1.9 m(520 k)(19.5 m)(32.5 m)(18.9 m)(27.1 m)

Depreciation and Amortization

4.6 m1.8 m3.6 m5.4 m3.7 m7.5 m11.2 m3.9 m9.9 m15.8 m5.6 m11.7 m

Inventories

(5 m)(5.3 m)(1.1 m)(19 m)(22.4 m)(20.6 m)

Cash From Operating Activities

20.1 m4.3 m23 m61.4 m(9.3 m)(6 m)16.2 m6.7 m(2.9 m)2.9 m(25.4 m)(15.1 m)
USDY, 2017

EV/EBIT

-3.4 x

EV/CFO

8.2 x

Revenue/Employee

985.4 k

Debt/Equity

0.1 x

Financial Leverage

2.3 x
Show all financial metrics
Report incorrect company information

Acorda Therapeutics News and Updates

Acorda Therapeutics explores sale: Wall Street Journal

Acorda Therapeutics Inc, a biotech company, is exploring a potential sale, the Wall Street Journal reported. It has hired investment banks Centerview Partners and MTS Health Partners, the story said. Proceedings are at an early stage; Acorda has a market value of $970 million, the WSJ said. Acorda’s…
Report incorrect company information